TNF and type 2 diabetes mellitus: Future studies should also evaluate the antigens and host markers in different study populations as such as children, individuals with immune suppression (e.g., due to HIV coinfection, therapy with TNF-α inhibitors, or due to type 2 diabetes), in TB patients after anti-TB therapy, in patients with extrapulmonary TB, and also in individuals with other lung diseases [49].